# **SECURITIES AND EXCHANGE COMMISSION** Washington, D.C. 20549

# **SCHEDULE 13G**

	UNDER THE SECURITIES EXCHANGE ACT OF 1934
	Adaptimmune Therapeutics PLC
-	(Name of Issuer)
	Ordinary Shares, par value GBP 0.001 per share
	(Title of Class of Securities)
	00653A107
	(CUSIP Number)
	12/31/2024
	(Date of Event Which Requires Filing of this Statement)
Check the appropriate b	ox to designate the rule pursuant to which this Schedule is filed:
✓ Rule 13d-1(b)	
Rule 13d-1(c)	
Rule 13d-1(d)	
	SCHEDULE 13G
CUSIP No.	00653A107

	CUSIP No.	00653A107
--	-----------	-----------

1	Names of Reporting Persons
	Two Seas Capital LP
	Check the appropriate box if a member of a Group (see instructions)
2	(a) (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE

Number of Shares Benefici ally Owned by Each Reporti	5	Sole Voting Power
		89,010,876.00
	6	Shared Voting Power
		0.00
	_	Sole Dispositive Power
ng Person	7	89,010,876.00
With:	0	Shared Dispositive Power
	8	0.00
Aggregate Amount Beneficially Owned by Each Reporting Person		e Amount Beneficially Owned by Each Reporting Person
9	89,010,876.00	
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
10		
Percent of class represented by amount in row (9)		f class represented by amount in row (9)
11	5.8 %	
40	Type of Reporting Person (See Instructions)	
12	IA, PN	

# SCHEDULE 13G

<b>No.</b> 00653A107
----------------------

1	Names of Reporting Persons	
'	Two Seas Capital GP LLC	
	Check the appropriate box if a member of a Group (see instructions)	
2	(a) (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization	
4	DELAWARE	
	5	Sole Voting Power
Number		89,010,876.00
of Shares Benefici ally Owned by Each Reporti ng Person With:	6	Shared Voting Power
		0.00
	7	Sole Dispositive Power
		89,010,876.00
	8	Shared Dispositive Power
		0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
9	89,010,876.00	
40	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
10		
<b>_</b>		

11	Percent of class represented by amount in row (9)
	5.8 %
12	Type of Reporting Person (See Instructions)
	OO, HC

# **SCHEDULE 13G**

<b>CUSIP No.</b> 00653A107
----------------------------

1	Names of Reporting Persons		
'	Sina Toussi		
	Check the appropriate box if a member of a Group (see instructions)		
2	□ (a) □ (b)		
3	Sec Use (	Only	
4	Citizenship or Place of Organization		
<u> </u>	UNITED S	STATES	
		Sole Voting Power	
Number	5	89,010,876.00	
Number of Shares	6	Shared Voting Power	
Benefici ally	6	0.00	
Owned by Each	7	Sole Dispositive Power	
Reporti ng Person With:	'	89,010,876.00	
	8	Shared Dispositive Power	
		0.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person		
Ŭ	89,010,876.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)		
11	Percent of class represented by amount in row (9)		
''	5.8 %		
12	Type of Reporting Person (See Instructions)		
12	IN, HC		

# **SCHEDULE 13G**

### Item 1.

(a) Name of issuer:

Adaptimmune Therapeutics PLC

(b) Address of issuer's principal executive offices:

60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom, X0 OX14 4R

#### Item 2.

Name of person filing: (a)

The Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons")

(i) Two Seas Capital LP ("TSC"); (ii) Two Seas Capital GP LLC ("TSC GP"); and

(iii) Sina Toussi.

This statement relates to Ordinary Shares, par value GBP 0.001 per share (the "Shares"), held by Two Seas Global (Master) Fund LP (the "Global Fund"). The principal business of TSC is providing investment advice as a registered investment adviser and serving as investment manager to the Global Fund. As such, TSC has been granted investment discretion over portfolio investments, including the Shares, held by or for the account of the Global Fund, including the Global Fund's voting and discretionary decisions. TSC GP serves as general partner of TSC. Sina Toussi serves as the chief investment officer of TSC and managing member of TSC GP

(b) Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is 32 Elm Place, 3rd Floor, Rye, New York 10580.

- Citizenship: (c)

  - (i) Two Seas Capital LP is a Delaware limited partnership; (ii) Two Seas Capital GP LLC is a Delaware limited liability company; and
  - (iii) Sina Toussi is a United States citizen.
- Title of class of securities: (d)

Ordinary Shares, par value GBP 0.001 per share

(e) **CUSIP No.:** 

00653A107

- Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
  - (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
  - Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (b)
  - (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  - Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (d)
  - (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  - An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (f)
  - A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (g)
  - (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  - (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  - A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § (j) 240.13d-1(b)(1)(ii)(J)

please specify the type of institution:

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). (k)

#### Item 4. Ownership

Amount beneficially owned: (a)

Amount beneficially owned as of December 31, 2024:

TSC - 89,010,876 Shares, represented by 14,835,146 American Depositary Shares TSC GP - 89,010,876 Shares, represented by 14,835,146 American Depositary Shares Sina Toussi - 89,010,876 Shares, represented by 14,835,146 American Depositary Shares

#### (b) Percent of class:

Percent of class as of December 31, 2024:

TSC - 5.8% TSC GP - 5.8% Sina Toussi - 5.8%

The Shares reported for Item 4 total 89,010,876 Shares, represented by 14,835,146 American Depositary Shares, held by the Global Fund. TSC may be deemed to have sole power to vote and sole power to dispose of the Shares held by the Global Fund, through its capacity as investment adviser of the Global Fund. TSC GP may be deemed to have sole power to vote and sole power to dispose of the Shares held by the Global Fund, through its capacity as general partner of TSC. Sina Toussi may be deemed to have sole power to vote and sole power to dispose of the Shares owned by the Global Fund, through his capacity as Managing Member of TSC GP.

The percentages reported for Item 4(b) are calculated based on a total of 1,535,299,242 Shares outstanding on November 12, 2024, as disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 13, 2024. %

#### (c) Number of shares as to which the person has:

#### (i) Sole power to vote or to direct the vote:

As of December 31, 2024, the Reporting Persons had sole power to vote or to direct the vote of 89,010,876 Shares.

#### (ii) Shared power to vote or to direct the vote:

As of December 31, 2024, the Reporting Persons had shared power to vote or to direct the vote of 0 Shares.

#### (iii) Sole power to dispose or to direct the disposition of:

As of December 31, 2024, the Reporting Persons had sole power to dispose or to direct the disposition of 89,010,876 Shares.

#### (iv) Shared power to dispose or to direct the disposition of:

As of December 31, 2024, the Reporting Persons had shared power to dispose or to direct the disposition of 0 Shares.

#### Item 5. Ownership of 5 Percent or Less of a Class.

#### Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

See disclosure in Item 4, which is incorporated by reference herein.

# Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See disclosure in Item 2, which is incorporated by reference herein.

#### Item 8. Identification and Classification of Members of the Group.

Not Applicable

#### Item 9. Notice of Dissolution of Group.

Not Applicable

#### Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

# Two Seas Capital LP

Signature: /s/ Sina Toussi

Sina Toussi / Managing Member of Two Seas Capital GP LLC, its General Partner Name/Title:

Date: 02/14/2025

# Two Seas Capital GP LLC

Signature: /s/ Sina Toussi

Name/Title: Sina Toussi / Managing Member

Date: 02/14/2025

# Sina Toussi

Signature: /s/ Sina Toussi Name/Title: Sina Toussi / Self

Date: 02/14/2025

#### JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the Ordinary Shares, par value £0.001 per share, of Adaptimmune Therapeutics plc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

EXECUTED as of this 14th day of February, 2025.

#### TWO SEAS CAPITAL LP

By: Two Seas Capital GP LLC, its general partner

By: /s/ Sina Toussi
Name: Sina Toussi
Title: Managing Member

### TWO SEAS CAPITAL GP LLC

By: /s/ Sina Toussi
Name: Sina Toussi
Title: Managing Member

#### SINA TOUSSI

By: /s/ Sina Toussi